Shanghai Fosun Pharmaceutical Group Co Ltd (600196)

Shanghai
Currency in CNY
25.92
+0.16(+0.62%)
Closed·
600196 Scorecard
Full Analysis
Trading at a low P/E ratio relative to near-term earnings growth
600196 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.6126.20
52 wk Range
21.6230.44
Key Statistics
Edit
Bid/Ask
25.92 / 25.93
Prev. Close
25.76
Open
25.78
Day's Range
25.61-26.2
52 wk Range
21.62-30.44
Volume
23.39M
Average Volume (3m)
16.88M
1-Year Change
8.04%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
600196 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
28.53
Upside
+10.06%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry
Show more

Shanghai Fosun Pharm Company Profile

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III. It engages in the import and export of medical equipment; provision of related and other consulting services; medical devices and diagnosis products, and healthcare service; and investment management, as well as involves in the retail and wholesale distribution of medicines. The company was founded in 1994 and is based in Shanghai, China.

Employees
40557
Market
China

Compare 600196 to Peers and Sector

Metrics to compare
600196
Peers
Sector
Relationship
P/E Ratio
21.6x22.6x−0.5x
PEG Ratio
0.47−0.440.00
Price/Book
1.3x2.1x2.6x
Price / LTM Sales
1.6x2.7x3.1x
Upside (Analyst Target)
1.1%10.5%47.0%
Fair Value Upside
Unlock12.5%−1.8%Unlock

Analyst Ratings

5 Buy
3 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 28.53
(+10.06% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.10%
Dividend Yield
1.04%
Industry Median 1.47%
Annualised payout
0.27
Paid annually
5-Years Growth
-3.88%
Growth Streak

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
0.29 / 0.295
Revenue / Forecast
9.42B / 10.29B
EPS Revisions
Last 90 days

600196 Income Statement

FAQ

What Is the Shanghai Fosun Pharm (600196) Stock Price Today?

The Shanghai Fosun Pharm stock price today is 25.92.

What Stock Exchange Does Shanghai Fosun Pharm Trade On?

Shanghai Fosun Pharm is listed and trades on the Shanghai Stock Exchange stock exchange.

What Is the Stock Symbol for Shanghai Fosun Pharm?

The stock symbol for Shanghai Fosun Pharm is "600196."

Does Shanghai Fosun Pharm Pay Dividends? What’s The Current Dividend Yield?

The Shanghai Fosun Pharm dividend yield is 1.04%.

What Is the Shanghai Fosun Pharm Market Cap?

As of today, Shanghai Fosun Pharm market cap is 63.23B.

What Is Shanghai Fosun Pharm's Earnings Per Share (TTM)?

The Shanghai Fosun Pharm EPS (TTM) is 1.10.

When Is the Next Shanghai Fosun Pharm Earnings Date?

Shanghai Fosun Pharm will release its next earnings report on 01 Sept 2025.

From a Technical Analysis Perspective, Is 600196 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Shanghai Fosun Pharm Stock Split?

Shanghai Fosun Pharm has split 7 times.

How Many Employees Does Shanghai Fosun Pharm Have?

Shanghai Fosun Pharm has 40557 employees.

What is the current trading status of Shanghai Fosun Pharm (600196)?

As of 12 Jun 2025, Shanghai Fosun Pharm (600196) is trading at a price of 25.92, with a previous close of 25.76. The stock has fluctuated within a day range of 25.61 to 26.20, while its 52-week range spans from 21.62 to 30.44.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.